U3-1402

DRUG2 trials

Sponsors

SCRI Development Innovations, LLC, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Advanced Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer

Phase 2

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

CompletedNCT04699630

SCRI Development Innovations, LLCLocally Advanced Breast Cancer, Metastatic Breast Cancer

Start: 2021-05-03End: 2025-04-09Updated: 2026-05-22

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

RecruitingNCT04965766

Gustave Roussy, Cancer Campus, Grand ParisAdvanced Breast Cancer, Metastatic Breast Cancer

Start: 2021-05-11End: 2030-04-11Target: 139Updated: 2025-12-23

Related Papers

Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial

Nature Medicine2025-09-042 citations

A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).

Journal of Clinical Oncology2023-06-0119 citations

189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

ESMO Open2023-05-0116 citations